ESR1 and neoplasm: Our findings suggest that many of patients who had elevated expression of tumor‐specific signatures such as ESR1, AR, VEGF, AKT1/2/3, CCND1, CDK1, and MMP9 had significantly poorer disease‐free survivals compared with the remaining subgroups.